Products

Online Inquiry

Name

Email *

Phone *

Company/Institution

Country or Region

Quantity

Services & Products Interested *

Project Description

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

LY2603618 (IC-83)

inquiry

Cat No.

CEI-0302

Description

LY2603618 (LCI-1) can inhibit CHK1 with IC550 of 7 nM.

CAS No.

911222-45-2

Molecular Weight

436.3

Purity

>99%

Storage

2 years at -20 centigrade

Targets

CHK1

Molecular Formula

C18H22BrN5O3

Chemical Name

(S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea

Solubility

DSMO 13 mg/mL Water

In vitro

LY2603618 (LCI-1) is an adenosine triphosphate-competitive inhibitor of Chk1, with IC50 of 7 nM with more than 50-fold selectivity for Chk1 inhibition as compared across a 100-member protein-kinase panel. In cell-based experiments LY2603618 (LCI-1) inhibited doxorubicin-dependent autophosphorylation of Chk1 with IC50 of 52 nM. Treated with 100 nM doxorubicin, HeLa cells arrested at the G2M checkpoint. When treated 24 hours later with LY2603618 (LCI-1), the arrested cells traversed the G2M checkpoint, allowing cells to proceed into mitosis with unresolved replicated chromosomes. Consistent with abrogation of the Chk1-dependent G2M checkpoint, HT-29 cells (mutant p53) treated with LY2603618 (LCI-1) were more sensitiveto killing by gemcitabine then were LY2603618 (LCI-1) treated HCT116 cells(wild-type p53).

In vivo

In vivo, LY2603618 (LCI-1) can effectively inhibit Chk1 autophosphorylation, as well as released the S and G2M block induced by gemcitabinetreatment. When used preclinically in combination with DNA damagingagents, LY2603618 (LCI-1) increased DNA damage and cell death over gemcitabinealone. LY2603618 (LCI-1) shows an effective potentiator of DNA damaging therapies in the clinic. In vivo xenograft studies have demonstrat- ed that LY2603618 in combination with pemetrexed or gemcitabine results in an increase in the antitumor effect compared to that observed in the respective chemotherapeutic agents when administered alone.